Competition and prices in the Mexican pharmaceutical market
The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolisti...
Gespeichert in:
| Veröffentlicht in: | Salud pública de México 2008, Vol.50 Suppl 4, p.S496 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | S496 |
| container_title | Salud pública de México |
| container_volume | 50 Suppl 4 |
| creator | Molina-Salazar, Raúl E González-Marín, Eloy Carbajal-de Nova, Carolina |
| description | The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high--according to aggregated estimates and prices for specific medicines--which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List. |
| doi_str_mv | 10.1590/S0036-36342008001000011 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_19082261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19082261</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-95f01bd1cf0c71484b9d2985d55e39cbf13215770835ca6e9841a2e44d1209cb3</originalsourceid><addsrcrecordid>eNo1j91KxDAUhIMg7rr6CpoXiJ6T_-CVFP9gxQv1ekmTU7a67ZY2C_r2FtS5GYaB4RvGLhGu0AS4fgVQViirtATwAAizEI_YEi1Y4QLaBTudpg8AqaRyJ2yBAbyUFpfsptp3A5W2tPuexz7zYWwTTbztedkSf6avNsWeD9s4djHRocxxx7s4flI5Y8dN3E10_ucr9n5_91Y9ivXLw1N1uxYDgi8imAawzpgaSA6113XIMniTjSEVUt2gkmicA69MipaC1xglaZ1RwtyrFbv43R0OdUd5MyPOAN-b_xfqB-A4SBM</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Competition and prices in the Mexican pharmaceutical market</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EBSCOhost Business Source Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Molina-Salazar, Raúl E ; González-Marín, Eloy ; Carbajal-de Nova, Carolina</creator><creatorcontrib>Molina-Salazar, Raúl E ; González-Marín, Eloy ; Carbajal-de Nova, Carolina</creatorcontrib><description>The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high--according to aggregated estimates and prices for specific medicines--which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List.</description><identifier>EISSN: 1606-7916</identifier><identifier>DOI: 10.1590/S0036-36342008001000011</identifier><identifier>PMID: 19082261</identifier><language>spa</language><publisher>Mexico</publisher><subject>Cost Control ; Drug Approval - economics ; Drug Costs ; Drug Discovery - economics ; Drug Industry - economics ; Economic Competition ; Economics ; Health Care Sector ; Health Policy ; Mexico ; Pharmaceutical Preparations - classification ; Pharmaceutical Preparations - economics ; Prescription Fees ; World Health Organization</subject><ispartof>Salud pública de México, 2008, Vol.50 Suppl 4, p.S496</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19082261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molina-Salazar, Raúl E</creatorcontrib><creatorcontrib>González-Marín, Eloy</creatorcontrib><creatorcontrib>Carbajal-de Nova, Carolina</creatorcontrib><title>Competition and prices in the Mexican pharmaceutical market</title><title>Salud pública de México</title><addtitle>Salud Publica Mex</addtitle><description>The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high--according to aggregated estimates and prices for specific medicines--which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List.</description><subject>Cost Control</subject><subject>Drug Approval - economics</subject><subject>Drug Costs</subject><subject>Drug Discovery - economics</subject><subject>Drug Industry - economics</subject><subject>Economic Competition</subject><subject>Economics</subject><subject>Health Care Sector</subject><subject>Health Policy</subject><subject>Mexico</subject><subject>Pharmaceutical Preparations - classification</subject><subject>Pharmaceutical Preparations - economics</subject><subject>Prescription Fees</subject><subject>World Health Organization</subject><issn>1606-7916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j91KxDAUhIMg7rr6CpoXiJ6T_-CVFP9gxQv1ekmTU7a67ZY2C_r2FtS5GYaB4RvGLhGu0AS4fgVQViirtATwAAizEI_YEi1Y4QLaBTudpg8AqaRyJ2yBAbyUFpfsptp3A5W2tPuexz7zYWwTTbztedkSf6avNsWeD9s4djHRocxxx7s4flI5Y8dN3E10_ucr9n5_91Y9ivXLw1N1uxYDgi8imAawzpgaSA6113XIMniTjSEVUt2gkmicA69MipaC1xglaZ1RwtyrFbv43R0OdUd5MyPOAN-b_xfqB-A4SBM</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Molina-Salazar, Raúl E</creator><creator>González-Marín, Eloy</creator><creator>Carbajal-de Nova, Carolina</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>2008</creationdate><title>Competition and prices in the Mexican pharmaceutical market</title><author>Molina-Salazar, Raúl E ; González-Marín, Eloy ; Carbajal-de Nova, Carolina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-95f01bd1cf0c71484b9d2985d55e39cbf13215770835ca6e9841a2e44d1209cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2008</creationdate><topic>Cost Control</topic><topic>Drug Approval - economics</topic><topic>Drug Costs</topic><topic>Drug Discovery - economics</topic><topic>Drug Industry - economics</topic><topic>Economic Competition</topic><topic>Economics</topic><topic>Health Care Sector</topic><topic>Health Policy</topic><topic>Mexico</topic><topic>Pharmaceutical Preparations - classification</topic><topic>Pharmaceutical Preparations - economics</topic><topic>Prescription Fees</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molina-Salazar, Raúl E</creatorcontrib><creatorcontrib>González-Marín, Eloy</creatorcontrib><creatorcontrib>Carbajal-de Nova, Carolina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Salud pública de México</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molina-Salazar, Raúl E</au><au>González-Marín, Eloy</au><au>Carbajal-de Nova, Carolina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Competition and prices in the Mexican pharmaceutical market</atitle><jtitle>Salud pública de México</jtitle><addtitle>Salud Publica Mex</addtitle><date>2008</date><risdate>2008</risdate><volume>50 Suppl 4</volume><spage>S496</spage><pages>S496-</pages><eissn>1606-7916</eissn><abstract>The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high--according to aggregated estimates and prices for specific medicines--which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List.</abstract><cop>Mexico</cop><pmid>19082261</pmid><doi>10.1590/S0036-36342008001000011</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1606-7916 |
| ispartof | Salud pública de México, 2008, Vol.50 Suppl 4, p.S496 |
| issn | 1606-7916 |
| language | spa |
| recordid | cdi_pubmed_primary_19082261 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EBSCOhost Business Source Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Cost Control Drug Approval - economics Drug Costs Drug Discovery - economics Drug Industry - economics Economic Competition Economics Health Care Sector Health Policy Mexico Pharmaceutical Preparations - classification Pharmaceutical Preparations - economics Prescription Fees World Health Organization |
| title | Competition and prices in the Mexican pharmaceutical market |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A56%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Competition%20and%20prices%20in%20the%20Mexican%20pharmaceutical%20market&rft.jtitle=Salud%20p%C3%BAblica%20de%20M%C3%A9xico&rft.au=Molina-Salazar,%20Ra%C3%BAl%20E&rft.date=2008&rft.volume=50%20Suppl%204&rft.spage=S496&rft.pages=S496-&rft.eissn=1606-7916&rft_id=info:doi/10.1590/S0036-36342008001000011&rft_dat=%3Cpubmed%3E19082261%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19082261&rfr_iscdi=true |